Fermenta Biotech Reports Q1FY27 Results: Consolidated Revenue at INR 126.2 Crore, Human Nutrition Volumes Up 18% QoQ

Fermenta Biotech Reports Q1FY27 Results: Consolidated Revenue at INR 126.2 Crore, Human Nutrition Volumes Up 18% QoQ​

Fermenta Biotech Limited, a major manufacturer of Vitamin D3 API and premium nutritional ingredients, announced its unaudited consolidated financial results for the quarter ended June 30, 2026. The company reported consolidated revenue (including real estate) at INR 126.2 crore, which represents a 13% year-on-year decline and was flat compared to the previous quarter.

For Q1FY27, EBITDA (other than from real estate) stood at INR 22.3 crore, marking a 37% decrease year-on-year and a 10% drop sequentially. When including real estate income, consolidated EBITDA was INR 22.4 crore, down 39% year-on-year and 11% quarter-on-quarter. The company reported Profit after Tax of INR 9.5 crore for the quarter, which saw a 56% decline year-on-year and 49% decline sequentially.

The year-on-year profit reduction was explained by factors outside the core business operations in Q1FY27, including a 40% fall in Vitamin D3 Animal Nutrition realisations, Other Income of INR 6.2 crore against INR 8.77 crore in the preceding quarter (which included a non-recurring insurance claim of INR 2.7 crore), and zero value from real estate unlocking, compared to INR 1.6 crore in Q1FY26.

Key Financial Highlights (Consolidated)​

The following tables detail the consolidated financial performance across different reporting metrics for Q1FY27.

Financial Performance (Consolidated)

Financial Performance (Excluding Real Estate)

Segmental Performance and Market Strength​

The company noted that while human nutrition volumes increased by 18% sequentially, the domestic market strengthened significantly. India accounted for 47% of consolidated revenue in Q1FY27, up from 35% a year earlier. Other APIs and Intermediates showed an 18% year-on-year rise. Green Chemistry Solutions/Enzymes grew by 15% year-on-year.

A detailed look at the business mix reveals:

Revenue Mix (Consolidated)

Geographical Revenue Mix (Excluding Real Estate)

Operational Highlights and Management Commentary​

Prashant Nagre, Managing Director, commented on the results, stating that "This was a quarter of building rather than harvesting." He noted that human nutrition volumes rose by 18% over the preceding quarter, and India’s contribution to consolidated revenue grew.

He added confidence points following key developments:

• The FSSAI approval for VITADEE Green®—Fermenta's plant-source Vitamin D3—received on July 6, 2026, allows it to be used as an ingredient in health supplements, nutraceuticals, food products, and large scale food fortification across India.
• In June 2026, Fermenta was ranked 7th nationwide among Great Mid-size Workplaces™ 2026 by Great Place To Work®.

The company also provided updates on various operational aspects:

• The animal nutrition segment volumes were down 52% sequentially and 20% year-on-year, with average realisation declining by 40% year-on-year.
• Subsidiary performance included the German subsidiary reporting revenue of INR 6.6 crore (down 58% YoY), and the US trading business subsidiary reporting revenue of INR 10.5 crore (up 36% QoQ).

Fermenta Biotech Limited is one of the world's largest Vitamin D3 API manufacturers, serving over 400 customers in more than 60 countries from facilities in Kullu, Dahej, and Tirupati. The company’s flagship products include VITADEE Green® plant-source Vitamin D3 and Vitamin D3 100 SD premix, which are supported by a granted Indian process patent.

FERMENTA Stock Price Movement​

As of 2:09 PM, shares of Fermenta Biotech Limited are shedding value in live trading, slipping 17.63% and currently priced at ₹451.35. The equity traded a volume of 649,555 shares during the current session.